VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis

American Journal of Gastroenterology

Volumn 100, Issue 7, 2005, Pages 1539-1546

  Bibiloni, Rodrigo ^a   Fedorak, Richard N ^a   Tannock, Gerald W ^a   Madsen, Karen L ^a   Gionchetti, Paolo ^b,c   Campieri, Massimo ^b,c   De Simone, Claudio ^d   Sartor, R Balfour ^e  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; MERCAPTOPURINE; MESALAZINE; NUCLEIC ACID BASE; PROBIOTIC AGENT;

ADULT; ARTICLE; BACTERIUM DETECTION; BLOATING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; DISEASE SEVERITY; DNA SEQUENCE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL ENDOSCOPY; GEL ELECTROPHORESIS; HUMAN; HUMAN TISSUE; INTESTINE BIOPSY; INTESTINE FLORA; MALE; MULTICENTER STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SIGMOIDOSCOPY; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADULT; COLITIS, ULCERATIVE; DNA, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROBIOTICS; REMISSION INDUCTION; RETREATMENT; TREATMENT OUTCOME;

EID: 22744438084     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.41794.x     Document Type: Article

References (42)

1. Sartor RB. Microbial influences in inflammatory bowel disease: Role in pathogenesis and clinical implications. In: Sartor RB, Sandborn WJ, eds. Kirsner's inflammatory bowel diseases: 6th Ed. London: Elsevier Publishers, 2004:138-62.
2. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998;66:5224-31.
3. Rath HC, Herfarth HH, Ikeda JS, et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest 1996;98:945-53.
4. Madsen KL, Doyle JS, Jewell LD, et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999;116:1107-14
5. Veltkamp C, Tonkonogy SL, de Jong YP, et al. Continuous stimulation by normal luminal bacteria is essential for the development and perpetuation of colitis in Tg(epsilon26) mice. Gastroenterology 2001;120:900-13.
6. Madsen KL, Malfair D, Gray D, et al. Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. Inflamm Bowel Dis 1999;5:262-70
7. Rath HC, Wilson KH, Sartor RB. Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus and Escherichia coli. Infect Immun 1999;67:2969-74.
8. Simon GL, Gorbach SL. Intestinal flora in health and disease. Gastroenterology 1984;86(1):174-93.
9. Favier C, Neut C, Mizon C, et al. Fecal beta-D-galactosidase production and bifidobacteria are decreased in Crohn's disease. Dig Dis Sei 1997;42(4):817-22.
10. Giaffer MH, Holdsworth CD, Duerden BI. The assessment of faecal flora in patients with inflammatory bowel disease by a simplified bacteriological technique. J Med Microbiol 1991;35(4):238-43.
11. Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 1998;115:1405-13.
12. Franchimont D, Vermeire S, El Housni H, et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 2004;53:987-92
13. Burke DA, Axon AT, Clayden SA, et al. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 1990;4:123-9.
14. Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991;32:1071-5.
15. Steinhart AH, Feagan BG, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn's disease: A randomized controlled trial. Gastroenterology 2002;123:33-340.
16. Fedorak RN, Madsen KL. Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis 2004;10:286-99.
17. Fedorak RN, Madsen KL. Probiotics and prebiotics in gastrointestinal disorders. Curr Opin Gastroenterol 2004;20:146-55
18. Guarner F, Schaafsma GJ. Probiotics. Int J Food Microbiol 1998;39:237-8.
19. Shanahan F. Probiotics and inflammatory bowel disease: Is there a scientific rationale? Inflamm Bowel Dis 2000;6:107-15.
20. Schultz M, Veltkamp C, Dieleman LA, et al. Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10 deficient mice. Inflamm Bowel Dis 2002;8:71-80.
21. Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001;121:580-91.
22. Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853-8.
23. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial [see comments]. Lancet 1999;354:635-9.
24. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: Preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999;13:1103-8.
25. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: Antibiotics, probiotics and prebiotics. Gastroenterology 2004;126:1620-33.
26. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003;15:697-8.
27. Borody TJ, Warren EF, Leis S, et al. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 2003;37:42-7.
28. Ishikawa H, Akedo I, Umesaki Y, et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003;22:56-63.
29. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis. Gastroenterology 2000;119:305-9.
30. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53:108-14.
31. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind placebo controlled trial. Gastroenterology 2003;124:1202-9.
32. Ulisse S, Gionchetti P, D'Alo S, et al. Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: Effects of probiotic treatment. Am J Gastroenterol 2001;96:2691-9.
33. Jijon H, Backer J, Diaz H, et al. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 2004;126:1358-73.
34. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987;92:1894-8.
35. Walter J, Tannock GW, Tilsala-Timisjarvi A, et al. Detection and identification of gastrointestinal Lactobacillus species by using denaturing gradient gel electrophoresis and species-specific PCR primers. Appl Environ Microbiol 2000;66:297-303.
36. Tannock GW, Munro K, Harmsen HJ, et al. Analysis of the fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosus DR20. Appl Environ Microbiol 2000;66:2578-88.
37. Tannock GW, Munro K, Bibiloni R, et al. Impact of consumption of oligosaccharide-containing biscuits on the fecal microbiota of humans. Appl Environ Microbiol 2004;70:2129-36
38. Zoetendal EG, von Wright A, Vilpponen-Salmela T, et al. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl Environ Microbiol 2002;68:3401-7.
39. Walter J, Hertel C, Tannock GW, et al. Detection of Lactobacillus, Pediococcus, Leuconostoc, and Weissella species in human feces by using group-specific PCR primers and denaturing gradient gel electrophoresis. Appl Environ Microbiol 2001;67:2578-85.
40. Brigidi P, Vitali B, Swennen E, et al. Specific detection of Bifidobacterium strains in a pharmaceutical probiotic product and in human feces by polymerase chain reaction. Syst Appl Microbiol 2000;23:391-9.
41. Vitali B, Candela M, Matteuzzi D, et al. Quantitative detection of probiotic Bifidobacterium strains in bacterial mixtures by using real-time PCR. Syst Appl Microbiol 2003;26:269-76.
42. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002;122:44-54.